# Erasca, Inc.: overview ERAS · Nasdaq · CIK 1761918 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eras.md) · [Financials](/companies/eras/financials.md) · [Filings](/companies/eras/filings.md) · [Insiders](/companies/eras/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.11)](/filings/0001193125-25-277625.md) | not reported | [(0.11)](/filings/0001193125-26-216788.md) | [(0.12)](/filings/0001193125-26-344611.md) | [(0.11)](/filings/0001193125-25-277625.md) | not reported | [(0.60)](/filings/0001193125-26-216788.md) | [(0.14)](/filings/0001193125-26-344611.md) | | Free cash flow | $m | [(22.4) d](/filings/0001193125-25-277625.md) | [(24.6) d](/filings/0001193125-26-104150.md) | [(31.6)](/filings/0001193125-26-216788.md) | [(20.6) d](/filings/0001193125-26-344611.md) | [(21.7) d](/filings/0001193125-25-277625.md) | [(21.7) d](/filings/0001193125-26-104150.md) | [(27.4)](/filings/0001193125-26-216788.md) | [(27.3) d](/filings/0001193125-26-344611.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.85)](/filings/0000950170-23-009496.md) | [(1.99)](/filings/0000950170-24-037193.md) | [(0.83)](/filings/0000950170-25-042682.md) | [(0.69)](/filings/0001193125-26-104150.md) | [(0.44)](/filings/0001193125-26-104150.md) | | Free cash flow | $m | [(90.8)](/filings/0000950170-23-009496.md) | [(118)](/filings/0000950170-24-037193.md) | [(103)](/filings/0000950170-25-042682.md) | [(109)](/filings/0001193125-26-104150.md) | [(95.6)](/filings/0001193125-26-104150.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eras/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $457.5m | 24,975,188 | | Added +300,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $387.5m | 21,154,146 | | Added +1,002,740 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $328.8m | 17,946,754 | | Added +1,789,579 | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $327.8m | 17,891,812 | | Added +1,509,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $223.2m | 12,184,555 | | Added +2,884,471 | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $222.6m | 12,150,000 | | Added +1,000,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $208.9m | 11,402,199 | | Added +152,461 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $208.8m | 11,397,781 | | Added +153,535 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $175.0m | 9,550,000 | | Reduced −842,702 | | [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $129.9m | 7,091,557 | | Unchanged | ## Recent filings [All 350 filings](/companies/eras/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 13:00 ET | [8-K](/filings/0001193125-26-423433.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-423433 | | 2026-08-24 | 12:15 ET | [8-K](/filings/0001193125-26-361895.md) | 8.01 Other events | 0001193125-26-361895 | | 2026-08-11 | 20:07 ET | [10-Q](/filings/0001193125-26-344611.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344611 | | 2026-08-11 | 20:05 ET | [8-K](/filings/0001193125-26-344584.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344584 | | 2026-08-10 | 21:14 ET | [8-K](/filings/0001193125-26-342669.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-342669 | | 2026-07-14 | 21:03 ET | [8-K](/filings/0001193125-26-303357.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-303357 | | 2026-07-13 | 20:19 ET | [8-K](/filings/0001193125-26-302045.md) | 8.01 Other events | 0001193125-26-302045 | | 2026-07-01 | 21:41 ET | [8-K](/filings/0001193125-26-290881.md) | 5.07 Shareholder vote results | 0001193125-26-290881 | | 2026-05-11 | 20:13 ET | [10-Q](/filings/0001193125-26-216788.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216788 | | 2026-05-11 | 20:05 ET | [8-K](/filings/0001193125-26-216739.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216739 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104150.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1761918 - Tickers: ERAS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.